

# Todd D Schell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5644646/todd-d-schell-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70  
papers

2,065  
citations

25  
h-index

44  
g-index

71  
ext. papers

2,420  
ext. citations

6  
avg, IF

4.4  
L-index

#	Paper	IF	Citations
70	Drug-tolerant persister cells in cancer therapy resistance.. <i>Cancer Research</i> , <b>2022</b> ,	10.1	2
69	A novel clinically relevant graft-versus-leukemia model in humanized mice. <i>Journal of Leukocyte Biology</i> , <b>2021</b> ,	6.5	2
68	TAMI-43. IMPACT OF SEX AND RADIATION ON IRON TRAFFICKING IN BONE MARROW DERIVED MACROPHAGES. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii222-ii222	1	
67	Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 674-684	4.5	8
66	EomesT-bet CD8 T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Cancer Research</i> , <b>2019</b> , 79, 1635-1645	10.1	27
65	Utility of concurrent immunoradiation for locally advanced and/or medically inoperable melanoma and Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e21053-e21053	2.2	
64	Increased circulating microparticles in streptozotocin-induced diabetes propagate inflammation contributing to microvascular dysfunction. <i>Journal of Physiology</i> , <b>2019</b> , 597, 781-798	3.9	6
63	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1539614	7.2	9
62	Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. <i>Gastroenterology</i> , <b>2018</b> , 154, 1024-1036.e9	13.3	69
61	Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 639-652	7.4	6
60	Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1405205	7.2	73
59	Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 34	7	32
58	PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological m̄age ¶rois. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 1669-1672	7.4	1
57	Persistent high levels of circulating effector memory T cells and anti-nuclear antibodies in metastatic melanoma patients who experience durable CRs to immunotherapy after the cessation of treatment.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21576-e21576	2.2	
56	Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 36-42	4.6	92
55	TCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006318	7.6	18
54	PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8 T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. <i>Journal of Immunology</i> , <b>2017</b> , 199, 3348-3359	5.3	44

53	Effects of chronic alcohol consumption on DNA damage and immune regulation induced by the environmental pollutant dibenzo[a,l]pyrene in oral tissues of mice. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , <b>2017</b> , 35, 213-222	4.5	8
52	Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 16932	4.9	21
51	Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. <i>Journal of Radiation Oncology</i> , <b>2017</b> , 6, 215-223	0.7	1
50	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 124	22.4	30
49	Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 75-85	13.4	38
48	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3057-66	12.9	154
47	Malignant melanoma-The cradle of anti-neoplastic immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 106, 25-54	7	22
46	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , <b>2016</b> , 45, 389-401	32.3	318
45	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 662-70	4.6	25
44	Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 325-36	7.4	2
43	Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. <i>European Journal of Nutrition</i> , <b>2015</b> , 54, 251-63	5.2	55
42	Purification of dendritic cell and macrophage subsets from the normal mouse small intestine. <i>Journal of Immunological Methods</i> , <b>2015</b> , 421, 1-13	2.5	17
41	In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine. <i>Vaccine</i> , <b>2014</b> , 32, 3274-84	4.1	9
40	Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 777-88	12.5	8
39	Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> , <b>2014</b> , 9, e90439	3.7	8
38	Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. <i>Comparative Medicine</i> , <b>2013</b> , 63, 338-41	1.6	2
37	Enhanced Glutathione Levels in Blood and Buccal Cells by Oral Glutathione Supplementation. <i>FASEB Journal</i> , <b>2013</b> , 27, 862.32	0.9	1
36	Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. <i>Hepatology</i> , <b>2012</b> , 55, 141-52	11.2	35

35	Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. <i>Journal of Immunology</i> , <b>2012</b> , 189, 5549-60	5.3	13
34	CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. <i>Journal of Immunology</i> , <b>2012</b> , 188, 4340-8	5.3	17
33	Circulating tumor cells in melanoma patients. <i>PLoS ONE</i> , <b>2012</b> , 7, e41052	3.7	59
32	Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. <i>Frontiers in Physiology</i> , <b>2011</b> , 2, 32	4.6	3
31	Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. <i>Journal of Immunology</i> , <b>2010</b> , 185, 2763-72	5.3	6
30	Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 1091-7	4.6	10
29	Poking CD40 for cancer therapy, another example of the Goldilocks effect. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 994-6	4.6	5
28	Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. <i>Journal of Vaccines &amp; Vaccination</i> , <b>2010</b> , 1,		6
27	Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. <i>Journal of Leukocyte Biology</i> , <b>2009</b> , 86, 1205-16	6.5	20
26	Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits. <i>Procedia in Vaccinology</i> , <b>2009</b> , 1, 4-14		2
25	An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. <i>Virology</i> , <b>2008</b> , 376, 183-90	3.6	7
24	TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. <i>Journal of Immunology</i> , <b>2008</b> , 181, 2563-71	5.3	38
23	CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. <i>Journal of Immunology</i> , <b>2008</b> , 181, 4406-17	5.3	27
22	Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 906-20	5	7
21	Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 883-94	7.4	8
20	Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. <i>Virology</i> , <b>2007</b> , 364, 155-68	3.6	4
19	Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. <i>Journal of Immunology</i> , <b>2007</b> , 179, 6686-95	5.3	12
18	Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. <i>Environmental Health Perspectives</i> , <b>2006</b> , 114, 1059-64	8.4	10

17	Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. <i>Journal of Immunology</i> , <b>2006</b> , 177, 255-67	5.3	11
16	An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. <i>Journal of Immunology</i> , <b>2006</b> , 177, 8037-45	5.3	38
15	Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. <i>Journal of Immunology</i> , <b>2006</b> , 177, 3089-99	5.3	25
14	Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. <i>Journal of Immunology</i> , <b>2005</b> , 175, 700-12	5.3	36
13	In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. <i>Journal of Virology</i> , <b>2004</b> , 78, 1751-62	6.6	11
12	Immune defects in 28-kDa proteasome activator gamma-deficient mice. <i>Journal of Immunology</i> , <b>2004</b> , 172, 3948-54	5.3	95
11	Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. <i>Journal of Immunology</i> , <b>2003</b> , 171, 4539-51	5.3	79
10	In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. <i>Journal of Immunology</i> , <b>2003</b> , 171, 697-707	5.3	64
9	The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 140, 13-27	3.5	49
8	The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. <i>International Immunology</i> , <b>2002</b> , 14, 775-82	4.9	9
7	Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. <i>Journal of Immunology</i> , <b>2001</b> , 167, 6947-56	5.3	28
6	Cytotoxic T lymphocytes in SV40 infections. <i>Methods in Molecular Biology</i> , <b>2001</b> , 165, 243-56	1.4	6
5	Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. <i>Journal of Virology</i> , <b>2000</b> , 74, 6922-34	6.6	83
4	Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. <i>Journal of Virology</i> , <b>1999</b> , 73, 5981-93	6.6	44
3	An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. <i>Journal of Virology</i> , <b>1998</b> , 72, 1469-81	6.6	61
2	Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 2141-9	6.1	6
1	The Immune Response to SV40, JCV, and BKV585-610		6